Preclinical Proof of Concept for the Single‐Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202502786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Kyu Tae Byun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Research Institute for Biomedical and Health Science, College of Biomedical and Health Science, Konkuk University, Ch…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Immunoconjugates, Antigens, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Ministry of Education, Republic of Korea, Ministry of Science and ICT, Republic of Korea, Chungbuk RISE Center.
Abstract (Originalsprache)
Although antibody‐drug conjugates (ADCs) are a widely used platform for developing various anticancer immunotherapeutics, the use of cancer non‐selective chemicals is recognized as a drawback of ADC development. To address the issues regarding the safety and manufacturing complexity of ADCs, this study conceptualizes a single‐protein platform, named dual‐targeting anticancer therapeutics (DTAT), that links a cancer cell‐selective cytotoxic peptide to an antibody via a linker peptide cleavable on cancer cells. As a model molecule for preclinical proof of the concept, an anti‐Her2 single‐chain variable fragment (scFv)‐based DTAT protein named DTAT‐D311 is established, which contains a recently developed anticancer peptide, herein named CPTin, as its cell‐penetrating payload. This recombinant single protein efficiently induces the apoptotic death of cancer cells, which is characterized by a very early onset. In terms of in vivo efficacy in suppressing tumor growth, DTAT‐D311 outperforms the anti‐Her2 therapeutic antibody, trastuzumab (Herceptin). By targeting an intracellularly addictive oncoprotein, CP2c, CPTin exhibits broad‐spectrum anticancer activity. In conclusion, this study demonstrates that DTAT provides an innovative pharmaceutical modality to target both a tumor surface antigen and an intracellular oncoprotein. In addition, DTAT‐D311 is suggested to be a promising biopharmaceutical agent for targeted immunotherapy against Her2‐positive cancers, exhibiting favorable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology and Research Institute for Biomedical and Health Science, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea.
- Department of Physiology, Ajou University School of Medicine, Suwon, Republic of Korea.
- Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea.
- Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Laboratory of Veterinary Medicine, College of Veterinary Toxicology, Kangwon National University, Chuncheon, Republic of Korea.
ORCID-Profile: Hyung-Sik Won
Förderung
- Ministry of Education, Republic of Korea
- Ministry of Science and ICT, Republic of Korea
- Chungbuk RISE Center
Zitieren
APA
Byun, K. T., Kim, B., Lee, I., Cho, J., Hwang, Y., Cheon, S. Y., Kang, H. C., Kim, C. G., Byun, J. W., Paeng, J. C., Park, D., Park, J. W., Kim, H., Chung, H. K., Won, H. S., & Kim, C. G. (2025). Preclinical Proof of Concept for the Single‐Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202502786
Vancouver
Byun KT, Kim B, Lee I, Cho J, Hwang Y, Cheon SY, et al. Preclinical Proof of Concept for the Single‐Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202502786
BibTeX
@article{Byun2025,
author = {Byun, Kyu Tae and Kim, Boram and Lee, Inbeom and Cho, Junmin and Hwang, Yiseul and Cheon, So Yeong and Kang, Ho Chul and Kim, Chul Geun and Byun, Jung Woo and Paeng, Jin Chul and Park, Dongsun and Park, Jang Woo and Kim, Heejung and Chung, Hye Kyung and Won, Hyung-Sik and Kim, Chan Gil},
title = {Preclinical Proof of Concept for the Single‐Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202502786}
}
EUVIMED